Overview
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.
For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.
View our corporate deck.
Share Price
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Annual Report 2021
Corporate Presentation
Cash at Parent Level
$377.9M PureTech Level Cash and Cash Equivalents as of March 31, 2022 1 with an addition of up to ~$115.4M from the
sale of KRTX shares on August 8, 2022, post-period*
1This represents a non-IFRS measure used by management for planning and reporting purposes. Please see below for a reconciliation of this measure to consolidated cash and cash equivalents, which is the most directly comparable measure calculated in accordance with IFRS:
PureTech Level Cash and Cash Equivalents is defined as cash and cash equivalents held at PureTech Health plc and its wholly-owned subsidiaries only. PureTech Level Cash and Cash Equivalents is an alternative performance measure which is adjusted and constitutes a non-IFRS measure. We believe that these non-IFRS performance measures, when provided in combination with IFRS measures, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial position from period to period. The measures are not substitutable for IFRS measures and should not be considered superior to measures presented in accordance with IFRS. These figures are unaudited and do not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2021 or March 31, 2022.
* Presumes the exercise of all call options written by the Company covering 477,100 Karuna shares with expiration dates in August and September 2022.